Amsacrine combined with etoposide and methylprednisolone is a
feasible and safe component in first-line intensified treatment of
pediatric patients with high-risk acute lymphoblastic leukemia in
CoALL08-09 trial
Kerstin Mezger MD1#, Sabine Ebert
MD1#, Hannah Elisa Muhle MD1, Udo
zur Stadt PhD1, Arndt Borkhardt2,
Dagmar Dilloo MD 3 Jörg Faber MD 4,
Tobias Feuchtinger MD 5, Thomas Imschweiler MD6, Norbert Jorch MD 7, Arnulf Pekrun
MD 8, Irene Schmid MD 5, Franziska
Schramm MD1, Martin Zimmermann PhD9, Martin A Horstmann MD1,* and
Gabriele Escherich MD1,*
1University Medical Centre Hamburg-Eppendorf, Clinic
of Paediatric Haematology and Oncology, Hamburg, Germany
2Department of Pediatric Oncology, Hematology and
Clinical Immunology, Medical Faculty Duesseldorf, Duesseldorf, Germany;
3Department of Pediatric Hematology/Oncology,
University Hospital Bonn, Bonn, Germany.
4Department of Pediatric Hematology/Oncology,
University Hospital Mainz, Mainz, Germany.
5Dr. von Hauner Children’s Hospital, Ludwig Maximilian
University, Munich, Germany.
6Department of Pediatric Hematology and Oncology,
Helios Hospital, Krefeld, Germany.
7Department of Pediatric Hematology and Oncology,
Hospital Bielefeld, Germany.
8Department of Pediatric Hematology and Oncology,
Hospital Bremen-Mitte, Germany.
9Department of Pediatric Haematology and Oncology,
Medical School Hannover, Hannover, Germany
# shared first authorship
* shared last authorship
Corresponding author:
PD Dr. med. Gabriele Escherich
Clinic of Paediatric Haematology and Oncology
University Medical Centre Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg
Tel.: 040 74105 3796
Fax.: 040 74105 8101
escherich@uke.de
Word count abstract: 246 words
Word count main text: 2758 words
Number of tables: 3 tables
Number of figures: 4 figures
Supporting information material: 6 supplemental figures, 1 supplemental
table
Short running title: Amsacrine in pediatric ALL therapy
Key words: Amsacrine, acute lymphoblastic leukemia, children